Selexis SA has been appointed for cell line development. KBI Biopharma, Inc. has been appointed for process development, analytical development, formulation development, and clinical manufacturing ...
Researchers at JAX will immediately begin leveraging CrownBio’s vast research services in oncology and CVMD to generate new insights into therapeutic approaches to target disease.
JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Sele...
Selexis’ SUREtechnology platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein, including those that are difficult to express in other systems
CrownBio has made the stable cell lines available for delivery, ready to be shipped overnight for next day delivery in the United States and within one week internationally.
Under the agreement, Progenics will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform™ for the development, manufacture, and commercialization of Progenics’ prostate specific...
Under the agreement, Liomont will have use of the Selexis CHO-M Cell Line™ and the SUREtechnology Platform for the development, manufacture and commercialization of an undisclosed antibody.
2 of 3
Receive JSR Life Sciences news on your RSS reader.